Aquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Aquestive Therapeutics (NASDAQ:AQST) released its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08), FiscalAI reports. The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded down $0.12 during trading on Wednesday, reaching $4.29. 2,157,673 shares of the company’s stock traded hands, compared to its average volume of 3,018,823. The stock has a market capitalization of $538.88 million, a P/E ratio of -7.03 and a beta of 1.49. Aquestive Therapeutics has a 12 month low of $2.93 and a 12 month high of $7.55. The company has a 50 day moving average of $4.13 and a 200-day moving average of $4.06.

Aquestive Therapeutics News Roundup

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Aquestive reported second-quarter revenue of $13.82 million, exceeding the $11.42 million analyst consensus. Management also provided a business update focused on advancing its product pipeline and preparing for potential commercialization. Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Previously announced topline human-factors and pharmacokinetic study results for Anaphylm, an epinephrine sublingual film intended to treat severe allergic reactions, showed encouraging performance. The results could support regulatory progress and strengthen the company’s commercial preparation efforts. Aquestive Announces Positive Anaphylm Study Results
• Neutral Sentiment: Reported August short-interest data showed zero shares sold short and a zero-day days-to-cover ratio. However, the figures appear inconsistent and provide little meaningful information about investor positioning.
• Negative Sentiment: Second-quarter adjusted loss widened to $0.18 per share from $0.14 a year earlier and missed the $0.10-per-share consensus estimate by $0.08. The result highlights continued operating losses as the company advances Anaphylm. Aquestive Therapeutics Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Aquestive’s fiscal 2026 revenue guidance of $46 million to $50 million is below the approximately $50.8 million consensus estimate. This outlook may weigh on the shares because it suggests slower near-term revenue growth than analysts expected.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer began coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.50.

Insider Buying and Selling

In related news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at $125,500. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 8,257 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $4.29, for a total transaction of $35,422.53. Following the completion of the sale, the chief executive officer owned 660,574 shares in the company, valued at $2,833,862.46. The trade was a 1.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. raised its holdings in Aquestive Therapeutics by 20.2% during the 4th quarter. Invesco Ltd. now owns 64,993 shares of the company’s stock worth $420,000 after buying an additional 10,920 shares during the period. Voloridge Investment Management LLC acquired a new position in shares of Aquestive Therapeutics in the fourth quarter worth about $1,254,000. Numerai GP LLC purchased a new position in shares of Aquestive Therapeutics in the fourth quarter worth approximately $789,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at approximately $365,000. Finally, Millennium Management LLC boosted its stake in Aquestive Therapeutics by 19.1% in the 4th quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock worth $9,918,000 after purchasing an additional 246,040 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.